Lenvatinib
Lenvatinib
Lenvatinib (pronounced len-VA-ti-nib) is a type of medication used primarily in the treatment of certain types of cancer. It is a multi-kinase inhibitor that works by blocking the action of certain proteins that signal cancer cells to grow and divide.
Etymology
The name "Lenvatinib" is derived from the pharmaceutical company Eisai Co.'s internal code for the drug, "E7080", and the "-nib" suffix common to kinase inhibitors.
Usage
Lenvatinib is used to treat differentiated thyroid cancer that is no longer responsive to radioactive iodine treatment. It is also used in combination with everolimus for the treatment of advanced renal cell carcinoma after one prior anti-angiogenic therapy, and for the treatment of hepatocellular carcinoma in patients who have not received prior systemic therapy.
Side Effects
Common side effects of Lenvatinib include hypertension, diarrhea, decreased appetite, weight loss, and nausea. Serious side effects can include liver problems, high blood pressure, heart problems, a type of lung problem known as pneumonitis, and kidney problems.
Related Terms
External links
- Medical encyclopedia article on Lenvatinib
- Wikipedia's article - Lenvatinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski